56 completed, 13 terminated, 12 unknown, 5 withdrawn. 92 Phase 2, 30 Phase 1, 1 Phase 3.
Follow Immunoblastic Lymphadenopathy: new trials by email Literature Review of Immunoblastic Lymphadenopathy trials Research Report on Immunoblastic Lymphadenopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Brincidofovir - Relapsed or Refractory Lymphoma Including ENKL | Phase 1 / Phase 2 | Suspended | SymBio Pharmaceuticals | 43 | 2025-06-09 | 2026-02-05 |
| Tazemetostat Plus CHOP in 1L T-cell Lymphoma Tazemetostat, Doxorubicin, Vincristine - Lymphoma, Peripheral T Cell Lymphoma | Phase 2 | Withdrawn | Eric Jacobsen, MD | 2024-12-24 | 2026-04-01 | |
| Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL mitoxantrone liposome 16 and azacitidine, mitoxantrone liposome 18 and azacitidine, mitoxantrone liposome 20 and azacitidine - Angioimmunoblastic T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huijing Wu | 30 | 2023-12-12 | 2024-01-25 |
| A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) BMS-986369 - Relapsed or Refractory T-cell Lymphomas | Phase 1 / Phase 2 | Active not recruiting | Bristol-Myers Squibb | 83 | 2023-11-20 | 2026-10-07 |
| Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma Azacitidine, Chidamide - Angioimmunoblastic T-cell Lymphoma | Phase 2 | Unknown | Peking Union Medical College Hospital | 20 | 2022-01-01 | 2022-01-05 |
| Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma Cyclophosphamide, Doxorubicin, Vincristine - Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 170 | 2021-10-08 | 2026-10-02 |
| Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL Sintilimab, Chidamide - Angioimmunoblastic T-cell Lymphoma | Phase 2 | Unknown | Sun Yat-sen University | 83 | 2021-04-15 | 2021-04-05 |
| Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma Brentuximab Vedotin, Pembrolizumab - Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 2 | Withdrawn | Northwestern University | 2020-03-01 | 2023-10-10 | |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 13 | 2019-02-25 | 2026-10-29 |
| Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma Chidamide, Cyclophosphamide, Doxorubicin - Angioimmunoblastic T-cell Lymphoma | Phase 2 | Unknown | Ruijin Hospital | 23 | 2018-12-29 | 2022-04-20 |
| Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma Venetoclax - T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory | Phase 2 | Terminated | Fondazione Italiana Linfomi - ETS | 22 | 2018-09-25 | 2023-12-12 |
| Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma AUTO4 - T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Terminated | Autolus Limited | 20 | 2018-08-30 | 2026-03-16 |
| Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Tislelizumab - Peripheral T Cell Lymphoma, PTCL | Phase 2 | Completed | BeiGene | 77 | 2018-04-13 | 2024-10-26 |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Pembrolizumab, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 38 | 2017-11-14 | 2026-10-28 |
| Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma Brentuximab Vedotin, Cyclophosphamide, Doxorubicin - Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative | Phase 2 | Active not recruiting | City of Hope Medical Center | 48 | 2017-05-25 | 2026-08-21 |
| Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Laboratory Biomarker Analysis, Nivolumab - Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma | Phase 2 | Terminated | Mayo Clinic | 12 | 2017-05-17 | 2020-04-21 |
| Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide) Chidamide - Angioimmunoblastic T-cell Lymphoma | Phase 2 | Unknown | Qingdao University | 30 | 2017-03-01 | 2017-09-25 |
| A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Brentuximab vedotin - T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 2 | Completed | Deepa Jagadeesh | 23 | 2016-06-17 | 2025-11-21 |
| CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma anti-CD7 CAR-pNK cells - Acute Myeloid Leukemia, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-03-01 | 2016-12-06 |
| Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Doxorubicin Hydrochloride - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 1 / Phase 2 | Completed | University of Nebraska | 54 | 2015-09-28 | 2023-12-13 |
Showing 20 of 92. Sign in to see all of them.
Lymphoma, Large-Cell, Anaplastic (73) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (59) · Lymphoma, Large B-Cell, Diffuse (55) · Lymphoma, Follicular (52) · Lymphoma, B-Cell, Marginal Zone (49) · Lymphoma, Mantle-Cell (49) · Lymphoma, Non-Hodgkin (49) · Leukemia, Lymphocytic, Chronic, B-Cell (48) · Lymphoma, T-Cell, Cutaneous (47) · Burkitt Lymphoma (46) · Mycosis Fungoides (46) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (46) · Waldenstrom Macroglobulinemia (46) · Hodgkin Disease (44)
Hemic and Lymphatic Diseases (92) · Immune System Diseases (92) · Immunoproliferative Disorders (92) · Lymphadenopathy (92) · Lymphatic Diseases (92) · Neoplasms by Histologic Type (86) · Lymphoproliferative Disorders (85) · Neoplasms (84) · Hematologic Diseases (63) · Leukemia, Lymphoid (62) · Lymphoma, T-Cell (59) · Lymphoma, B-Cell (57) · Disease Attributes (54) · Pathologic Processes (54) · Pathological Conditions, Signs and Symptoms (54)
Cyclophosphamide (27) · fludarabine phosphate (19) · Peripheral Blood Stem Cell Transplantation (15) · Mycophenolic Acid (12) · Vincristine (12) · Whole-Body Irradiation (12) · Doxorubicin (11) · Etoposide (11) · Prednisone (11) · Cyclosporine (10) · Tacrolimus (10) · Antilymphocyte Serum (8) · Busulfan (8) · Melphalan (7) · Methotrexate (7)
Fred Hutchinson Cancer Center (10) · National Cancer Institute (NCI) (9) · Mayo Clinic (6) · City of Hope Medical Center (5) · M.D. Anderson Cancer Center (4) · Northwestern University (4) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Memorial Sloan Kettering Cancer Center (3) · Northside Hospital, Inc. (3) · Case Comprehensive Cancer Center (2) · Fondazione Italiana Linfomi - ETS (2) · Roswell Park Cancer Institute (2) · University of Nebraska (2) · University of Washington (2) · Acrotech Biopharma Inc. (1)
United States (66) · China (9) · Italy (9) · France (6) · Canada (4) · United Kingdom (4) · Belgium (3) · South Korea (3) · Egypt (2) · Germany (2) · Japan (2) · Netherlands (2) · Singapore (2) · Switzerland (2) · Croatia (1)
Brenda Sandmaier (3) · Ajay Gopal (2) · Alex F Herrera (2) · David Maloney (2) · Jonathan Moreira, MD (2) · Scott R. Solomon, MD (2) · Adam Petrich, MD (1) · Anas Younes (1) · Andre Goy (1) · Asad Bashey, MD, PhD (1) · Auayporn P. Nademanee, MD (1) · Barbara Pro, MD (1) · Charles L. Loprinzi, M.D. (1) · Claudio Anasetti, MD (1)
PMID 32499241, PMID 18327587, PMID 19170225, PMID 19841031, PMID 19900571, PMID 20142598, PMID 20166206, PMID 20229590, PMID 20942843, PMID 21135857, PMID 24241210, PMID 25921059, PMID 26077240, PMID 26213141, PMID 26688485, PMID 26764356, PMID 28054442, PMID 28314788, PMID 29703335, PMID 32349779, PMID 34938664, PMID 35170082, PMID 35750419, PMID 37276067, PMID 37327113, PMID 39067464, PMID 39528665, PMID 39821757
P30CA015704 (7), P30CA015083 (4), P30CA033572 (4), P01CA018029 (3), 2017 (2), P01CA078902 (2), P30CA008748 (2), P30CA036727 (2), P30CA060553 (2), U10CA021115 (2), 2014 (1), N01CM00039 (1), N01CM00070 (1), N01CM17003 (1), N01CM62202 (1)